Drug Found to Fight Marfan (Australia)
This article was originally published in PharmAsia News
Executive Summary
Researchers at the Baker Heart Research Institute in Melbourne, Australia, have discovered an existing drug that may be helpful for treating Marfan syndrome. The drug, called perindopril, works to reduce the fragility of the aorta. Aortic rupture is the leading cause of death in people with Marfan, which is a genetic condition that causes imperfections in the connective tissues of the body's skeletal, ocular, and cardiovascular systems. Up until now, most patients with Marfan had to take beta-blockers to slow their heart rate in an attempt to prevent stress on the aorta. But these drugs do nothing to strengthen the aorta and Marfan sufferers often have to undergo multiple heart surgeries, which are both expensive and risky. Scientists say using perindopril will cut down on the need for those surgeries, increasing the quality of life for those with the disease. (Click here for more
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.